DSM-Firmenich

Running down

13/02/20 -"Or perfect timing. The reported 2019 figures were not bad and broadly confirmed our view on the company and the street’s expectations. But they were not glittering like at other companies when ..."

PDF page sample
Pages
60
Language
English
Published on
13/02/20
Download
You may also be interested by these reports :
21/01/26
We have lowered our EPS estimates for FY25/FY26 to -€0.91/€0.45, from €1.15/€3.57, reflecting weaker sales expectations (FY25/FY26: €5.5bn/€5.6bn vs ...
14/01/26
Cost discipline helps, but delivery still falls short
04/12/25
We last highlighted Umicore (Reduce, Belgium) in November 2021, when the stock began to fall from its all-time high of €60.0. Since then, the share ...
25/11/25
The EPS change for 2025 reflects our more conservative opinion of EBITDA (discussed in DCF section) and earnings from investment accounted using ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO